Every 10-Q that Amarin Corp Plc (AMRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMRN filings page.
Amarin Corporation reported Q2 2026 net revenue of $42,211 (amounts in thousands), down from $72,741 a year earlier, as product sales softened and prior-year licensing milestones did not recur. Cost of goods sold rose to $27,222, compressing gross margin to $14,989 and driving an operating loss of $12,010.
Net loss narrowed to $7,650 for the quarter and $18,162 for the first half of 2026, helped by lower operating expenses and higher interest income. Cash and short-term investments totaled $314.6 million within total assets of $624.4 million at June 30, 2026, and the company had no debt, with net cash provided by operating activities of $12,992 year-to-date.
The 2025 Global Restructuring Plan is effectively winding down, with cumulative restructuring charges of $39.6 million and a remaining liability of $2,587 (in thousands). Litigation-related charges were $6.3 million in Q2, including a confidential settlement with certain purchaser plaintiffs, while VASCEPA/VAZKEPA remains the core cardiovascular franchise across U.S., European and other global markets.
Amarin Corporation reported a Q1 2026 net loss of $10.5 million, improving from $15.7 million a year earlier, as revenue edged up and operating costs fell. Total revenue reached $45.1 million, including $43.3 million of product sales and $1.8 million of licensing and royalty income.
Gross margin declined as cost of goods sold rose to $27.4 million, but selling, general and administrative expenses dropped sharply to $21.1 million, partly reflecting restructuring. The company recorded $3.3 million of restructuring expense and $3.1 million of litigation settlements. Amarin ended the quarter with $307.8 million in cash and short‑term investments, total assets of $645.8 million, and no debt, while generating $6.4 million of cash from operating activities.
Amarin Corporation plc reported Q3 2025 results. Total revenue was $49.7 million (up from $42.3 million a year ago), driven by product revenue of $48.6 million and licensing and royalty revenue of $1.1 million. The company posted a net loss of $7.7 million, a significant improvement from a $25.1 million loss in Q3 2024, as operating expenses declined, particularly selling, general and administrative costs.
Gross margin was $22.2 million on cost of goods sold of $27.5 million. Amarin recorded $9.4 million of restructuring expense in the quarter and $32.2 million year‑to‑date tied to its June 24, 2025 global restructuring plan associated with its Recordati agreement, with expected total charges of $30.0–$37.0 million, substantially all cash.
Liquidity remains solid with $122.8 million in cash and cash equivalents and $163.8 million in short‑term investments as of September 30, 2025, and no outstanding debt. Year‑to‑date, revenue was $164.4 million and net loss $37.6 million. U.S. product revenue led the quarter at $40.9 million, with Europe at $4.1 million and Rest of World at $3.6 million.